Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
FDA approved Zycubo, copper histidinate injection, as the first treatment for children with Menkes disease.
Menkes disease is a rare disorder of copper transport that can cause severe neurologic and developmental problems.
The approval is a rare-disease milestone because first treatments can change diagnosis urgency, newborn evaluation and specialist referral patterns.
Why It Matters
First therapies for rare pediatric diseases can reshape clinical pathways and family expectations.
What to Watch
Watch access, early diagnosis and long-term outcome data in treated children.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAMenkes DiseaseRare DiseasePediatrics